

Docket No.: B1136.70000US03

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Edward P. Ingenito

Serial No .:

10/069,307

Confirmation No.:

1962

Filed:

September 26, 2002

For:

TISSUE VOLUME REDUCTION

Examiner:

C. S. Williams

Art Unit:

3763

Certificate of Mailing Under 37 CFR 1.8(a)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: 8/11/07

Signature

(Trish McDonald

INFORMATION DISCLOSURE STATEMENT (IDS)

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action after the filing of a Request for Continued Examination under 37 CFR 1.114 (37 CFR 1.97(b)(4)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

The Applicant would like to bring to the Examiner's attention the enclosed search report or other communication from a corresponding International or Foreign National Application.

Serial No.	Mailing Date	Type(s) of Communication	Docket No.
PCT/US00/23134	02/27/2001	International Search Report	B1136.70000WO00
PCT/US00/23134	08/02/2001	Written Opinion	B1136.70000WO00
PCT/US00/23134	10/25/2001	International Preliminary Examination Report	B1136.70000WO00
EP 04024842	03/03/2005	Partial European Search Report	B1136.70000EP01

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 23/2825, under Docket No. B1136.70000US03. A duplicate copy of this paper is enclosed.

Dated: August 6, 2007

Respectfully submitted,

Patrick R.H. Waller

Registration No.: 41,418

WOLF, GREENFIELD & SACKS, P.C.

Federal Reserve Plaza 600 Atlantic Avenue

Boston, Massachusetts 02210-2206

(617) 646-8000

Used in Lieu of PTO/SB/08A/B (Based on PTO 04-07 version)

Substitute for form 1449/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

1 of 4

	(Baseu OII P TO 04-07 VEISION)
	Complete if Known
Application Number	10/069,307-Conf. #1962
Filing Date	September 26, 2002
First Named Inventor	Edward P. Ingenito
Art Unit	3763
Examiner Name	C. S. Williams
Attorney Docket Number	B1136.70000US03

	U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	US-20030099601-A1	05-29-2003	Gordon et al.	
	A2	US-20030114384-A1	06-19-2003	Podolsky	
	A3	US-20030134810-A1	07-17-2003	Springate et al.	
	A4	US-20030181356-A1	09-25-2003	Ingenito	
	A5	US-20040038868-A1	02-26-2004	Ingenito	
	A6	US-20040047855-A1	03-11-2004	Ingenito	
	A7	US-20050130176	06-16-2005	Vogelstein et al.	
	A8*	US-3,089,815	05-14-1963	Lieb et al.	
	A9	US-4,013,507	03-22-1977	Rembaum	
	A10	US-4,393,041	07-18-1983	Brown et al.	
	A11	US-4,442,655	04-17-1984	Stroetmann	
	A12	US-4,619,913	10-28-1986	Luck	
	A13	US-4,631,055	12-23-1986	Redl et al.	
	A14	US-4,719,282	01-12-1988	Nadolsky et al.	
	A15	US-4,973,582	11-27-1990	Yoshida et al.	
	A16	US-5,290,552	03-23-1992	Sierra et al.	
	A17	US-5,583,114	12-10-1996	Barrows et al.	
	A18	US-5,651,982	07-29-1997	Marx	
	A19	US-5,660,175	08-26-1997	Dayai	
	A20	US-5,690,675	11-25-1997	Sawyer et al.	
	A21	US-5,714,470	02-03-1998	Peet et al.	·
	A22	US-5,780,440	07-14-1998	Lezdey et al.	
		US-5,836,905	11-17-1998	Lemelson et al.	
	A24	US-5,883,084	03-16-1999	Peterson et al.	
		US-5,980,866	11-09-1999	Uchida et al.	
	A26	US-6,001,814	12-14-1999	Gyorkos et al.	
	A27	US-6,117,425	09-12-2000	MacPhee et al.	
	A28	US-6,123,663	09-26-2000	Rebuffat et al.	
	A29	US-6,258,100	07-10-2001	Alferness et al.	
	A30	US-6,293,951	09-25-2001	Alferness et al.	
	A31	US-6,333,194	12-25-2001	Levy et al.	
	A32	US-6,592,594	07-15-2003	Rimbaugh et al.	
	A33	US-6,599,311	07-29-2003	Biggs et al.	
	A34	US-6,645,205	11-11-2003	Ginn	
	A35	US-6,837,906	01-04-2005	Ginn	
	A36	US-6,878,141	04-12-2005	Perkins et al.	
	A37	US-6,886,558	05-03-2005	Tanaka	
	A38	US-6,929,637	08-16-2005	Gonzalez et al.	

	FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
	B1	EP-0627266	12-07-1994	Aid Medic Ltd		
	B2	EP-1206276	05-22-2002	Ingenito Edward P		
	В3	RU-2092108	10-10-1997	Vecherko Vladimir Nikolaevich et al.		lacksquare

Examiner	Date
Signature	Considered

Complete if Known Substitute for form 1449/PTO Application Number 10/069,307-Conf. #1962 INFORMATION DISCLOSURE Filing Date September 26, 2002 STATEMENT BY APPLICANT First Named Inventor Edward P. Ingenito Art Unit 3763 (Use as many sheets as necessary) C. S. Williams Examiner Name Sheet 2 of 4 B1136.70000US03 Attorney Docket Number

B4	RU-2130946	05-27-1999	Ehmakjur Biotek Ink	
B5	WO-0113908	03-01-2001	Ingenito Edward P	
B6	WO-0126721	04-19-2001	Univ Boston et al.	
В7	WO-03105676	12-24-2003	Bistech Inc et al.	
B8	WO-9209301	06-11-1992	American Nat Red Cross et al.	
В9	WO-9213547	08-20-1992	Eaton et al.	
B10	WO-9407607	04-14-1994	Boehringer Ingelheim Int et al.	
B11	WO-9613292	05-09-1996	Aradigm Corp	
B12	WO-9616983	06-06-1996	Jolla Cancer Res Found	
B13	WO-9729851	08-21-1997	Technology Partnership et al.	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	[No Author Listed] Surfactant replacement therapy for respiratory distress syndrome. American Academy of Pediatrics. Committee on Fetus and Newborn. Pediatrics. 1999 Mar;103(3):684-5.	
,	C2	[No Author Listed] Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med. 1980 Sep;93(3):391-8.	
	C3	BAUMANN et al., Closure of a bronchopleural fistula using decalcified human spongiosa and a fibrin sealant. Ann Thorac Surg. 1997 Jul;64(1):230-3.	
	C4	BERLIN et al., Are porphyrin mixtures favorable photodynamic anticancer drugs? A model study with combinatorial libraries of tetraphenylporphyrins. Comb Chem. 1998;61:107-8.	
	C5	CAMILLI et al., Longitudinal changes in forced expiratory volume in one second in adults. Effects of smoking and smoking cessation. Am Rev Respir Dis. 1987 Apr;135(4):794-9.	
	C6	CARR et al., Effect of homo poly(L-amino acids) on fibrin assembly: role of charge and molecular weight. Biochemistry, Vol. 28, No. 3 (1989) 1388-1395.	
	C7	CARR et al., Effect of glycosaminoglycans on Thrombin- and atroxin-induced fibrin assembly and structure. 62(4) 1057-1061 (1989).	
	C8	COYLE et al., Human eosinophil-granule major basic protein and synthetic polycations induce airway hyperresponsiveness in vivo dependent on bradykinin generation. J Clin Invest. 1995 Apr;95(4):1735-40.	
	C9	DALLAS et al., Measuring interactions between ECM and TGFß-like proteins. Chapter 19: Methods in Molecular Biology. 2000;139:231-43.	
	C10	DANIEL et al., Lung volume reduction surgery. Case selection, operative technique, and clinical results. Ann Surg. 1996 May;223(5):526-31; discussion 532-3.	
	C11	DEYERLING et al., A suspension of fibrin glue and antibiotic for local treatment of mycotic aneurysms in endocarditisan experimental study. Thorac Cardiovasc Surg. 1984 Dec;32(6):369-72.	
	C12	DRUMMOND et al., Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev. 1999 Dec;51(4):691-743.	
	C13	FESSLER et al., Lung volume reduction surgery and airflow limitation. Am J Respir Crit Care Med. 1998 Mar;157(3 Pt 1):715-22.	
	C14	FOK et al., Randomised controlled study of early use of inhaled corticosteroid in preterm infants with respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed. 1999	

Examiner		Date	
Signature		Considered	ľ

Substitute for form 1449/PTO

3

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

4

		Complete if Known		
	Application Number	10/069,307-Conf. #1962		
	Filing Date	September 26, 2002		
	First Named Inventor	Edward P. Ingenito		
	Art Unit	3763		
	Examiner Name	C. S. Williams		
	Attorney Docket Number	B1136.70000US03		

	May;80(3):F203-8.	
C1	Respir Crit Care Med. 2001 Jun;163(7):1562-6.	
C1	Biol Chem. 1984 Mar 10;259(5):3248-53.	
C1	GOLAB et al., Potentiation of the anti-tumour effects of Photofrin-based photodynamic therapy by localized treatment with G-CSF. Br J Cancer. 2000 Apr;82(8):1485-91.	
C1	destructive lesions of the lungs and pleura. Synopsis of the Candidate of Sciences degree thesis. 1988. Russian	1
C1	GUSTAFSSON et al., The 21-residue surfactant peptide (LysLeu4)4Lys(KL4) is a transmembrane alpha-helix with a mixed nonpolar/polar surface. FEBS Lett. 1996 Apr 15;384(2):185-8.	
C2	1992 Aug;73(2):427-33.	
C2	emphysema in mice. Science. 1997 Sep 26;277(5334):2002-4.	
C2	Jul;47(7):565-7.	
C2	INGENITO et al., Biophysical characterization and modeling of lung surfactant components. J Appl Physiol. 1999 May;86(5):1702-14.	
C2	surfactant. Am J Respir Crit Care Med. 2000 Mar;161(3 Pt 1):831-8.	
C2	reduction surgery. Am J Respir Crit Care Med. 2001 Apr;163(5):1068-73.	
C2	INGENITO et al., Interpreting improvement in expiratory flows after lung volume reduction surgery in terms of flow limitation theory. Am J Respir Crit Care Med. 2001 Apr;163(5):1074-80.	
C2	INGENITO et al., Bronchoscopic volume reduction: a safe and effective alternative to surgical therapy for emphysema. Am J Respir Crit Care Med. 2001 Jul 15;164(2):295-301.	
C2		
C2	ITOH et al., [A fibrin clot containing of anticancer drug for intra-arterial chemo-embolization therapy. (1) Experimental study on basic characteristics in dogs] Gan To Kagaku Ryoho. 1985 Feb;12(2):250-7. Japanese.	
СЗ	KÖNIG et al., Pdt of tumor-bearing mice using liposome delivered texaphyrins. International Conference, Milan, Italy. June 24-27, 1992.	
СЗ	elastase-induced emphysema. Am J Respir Crit Care Med. 2001 Nov 15;164(10 Pt 1):1920-6.	
C3		
СЗ		
СЗ		
СЗ		
C3	LIN et al., Induction of pulmonary fibrosis in organ-cultured rat lung by cadmium chloride and transforming growth factor-beta1. Toxicology. 1998 May 15;127(1-3):157-66.	

Examiner	{[Date	
Signature		Considered	

Substitute for form 1449/PTO

4

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of

4

Complete if Known		
Application Number	10/069,307-Conf. #1962	
Filing Date	September 26, 2002	
First Named Inventor	Edward P. Ingenito	
Art Unit	3763	
Examiner Name	C. S. Williams	
Attorney Docket Number	B1136.70000US03	

C37	LIPP et al., Phase and morphology changes in lipid monolayers induced by SP-B protein and its amino-terminal peptide. Science. 1996 Aug 30;273(5279):1196-9.		
C38	ICKENNA et al., Should lung volume reduction for emphysema be unilateral or bilateral? J horac Cardiovasc Surg. 1996 Nov;112(5):1331-8; discussion 1338-9.		
C39	LEAN et al., An amphipathic alpha-helical decapeptide in phosphatidylcholine is an ective synthetic lung surfactant. Am Rev Respir Dis. 1993 Feb;147(2):462-5.		
C40	NEY et al., Fibrin glue-antibiotic suspension in the prevention of prosthetic graft infection. J Trauma. 1990 Aug;30(8):1000-5; discussion 1005-6.		
C41	LSSON et al., Synthetic peptide-containing surfactantsevaluation of transmembrane ersus amphipathic helices and surfactant protein C poly-valyl to poly-leucyl substitution. Eur Jochem. 1998 Jul 1;255(1):116-24.		
C42	OTIS et al., Dynamic surface tension of surfactant TA: experiments and theory. J Appl Physiol. 1994 Dec;77(6):2681-8.		
C43	PASS et al., Photodynamic therapy in oncology: mechanisms and clinical use. J Natl Cancer Inst. 1993 Mar 17;85(6):443-56.		
C44	RICHERT et al., A long-time-stable liposome formulation for porphyrinoid photosensitizers. J Photochem Photobiol B: Biol. 1993;19:67-73.		
C45	SHAPIRO et al., The macrophage in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 2):S29-32.		
C46	SIME et al., Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J Clin Invest. 1997 Aug 15;100(4):768-76.		
C47	SMITH et al., Activity of two polyene and two imidazole antimicrobics on Candida albicans in human fibrin clots. J Lab Clin Med. 1983 Jul;102(1):126-32.		
C48	SUGITACHI et al., Japan J Cancer Chemother 16(8)2814-2817 August 1989. (Abstract)		
C49	SUKI et al., On the progressive nature of emphysema: roles of proteases, inflammation and mechanical forces. Am. J. of Resp. and Critical Care Med. Vol. 168 516-521 (2003).		
C50	VAROLI et al., Endoscopic treatment of bronchopleural fistulas. Ann Thorac Surg. 1998 Mar;65(3):807-9.		
C51	WHITMAN et al., TGF-beta superfamily signaling and left-right asymmêtry. Sci STKE. 2001 Jan 9;2001(64):RE1.		
C52	YANAGISAWA et al., [Endoscopic closure of the postoperative bronchopleural fistula] Kyobu Geka. 1992 Oct;45(11):975-8. Japanese.		
C53	IESCHE et al., A preliminary study of long-term treatment with interferon gamma-1b and low- ose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 1999 Oct 1;341(17):1264-9. Erratum in: N Engl J Med 2000 Feb 17;342(7):524.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filling date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Consideration of the state of t	l Dete	
Examiner	Date	. 1
Signature	Considere	ed